Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Cancer Immunol Immunother. 2016 Aug 31;65(11):1353–1364. doi: 10.1007/s00262-016-1893-7

Fig. 1. Overall survival is increased with the addition of IFN-α-2b.

Fig. 1

(a) Progression-free survival curves comparing those patients not receiving IFN-α-2b (Cohort 0) to those receiving any dose of IFN-α-2b (Cohorts 1–4). (b) Overall survival curves comparing those patients not receiving IFN-α-2b (cohort 0) to those receiving any dose of IFN-α-2b (Cohorts1–4) (c) Progression-free survival curves and (d) overall survival curves comparing all 5 study arms: Cohort 0, no IFN-α-2b; Cohort 1, IFN-α-2b (1×106 U); Cohort 2, IFN-α-2b (3×106 U); Cohort 3, IFN-α-2b (6×106 U); Cohort 4, IFN-α-2b (9×106 U)